The FDA expanded the approval of GSK's respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at ...
The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Moderna has received the Food and Drug Administration’s approval for RESVIA (mRNA-1345), an mRNA respiratory syncytial virus ...
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for ...
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 ...
Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for their ...
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased ...
Moderna's RSV vaccine, the first RSV vaccine to use mRNA, earned FDA approval for adults 60 and up. Here's what you need to ...
For the first time, an RSV vaccine has been approved for use in adults in their fifties. GSK's Arexy appears to have similar ...
The decision comes just over a year after the FDA approved Arexvy for use in adults aged 60 years and older GSK’s Arexvy has become the first respiratory syncytial virus (RSV) vaccine to be approved ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.